Placebo News and Research

RSS

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

There are two traits closely associated with the development of alcohol use disorders (AUDs). One is a lower subjective intoxication response, also known as a low level of response to alcohol.

12 Aug 2013

Researchers discover new treatment for children with fragile bone disease

A new treatment for children with brittle bone disease has been developed by the University of Sheffield and Sheffield Children's Hospital.

12 Aug 2013

Probiotic supplements have no effect on the incidence of diarrhoea in elderly patients

Probiotic supplements given to elderly patients on antibiotics appear to have no effect on the incidence of diarrhoea, a common and sometimes life-threatening side effect of using antibiotics for many elderly patients, according to a new study published in The Lancet.

9 Aug 2013

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.

8 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Contrary to past concerns, using prolonged exposure therapy to treat patients with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence does not increase drinking or cravings, Penn Medicine psychiatrists report in the August 7 issue of JAMA, a theme issue on violence/human rights.

7 Aug 2013

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA).

6 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

New technique accelerate tissue repair, reduce costs for chronic wound management

In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.

2 Aug 2013

Pharmanest announces positive results from SHACT Phase II study

Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.

1 Aug 2013

Experts say action needed urgently to ensure India's new policy does not backfire

In an editorial published online today in BMJ, Johns Hopkins bioethicist Jeremy Sugarman and other experts warn that action is urgently needed to deal with possible unintended consequences of India's new policy protecting research participants.

1 Aug 2013

Oxytocin hormone affects men and women differently, research finds

"The Love Hormone", Oxytocin affects men and women differently in social contexts- in men it improves the ability to identify competitive relationships whereas in women it facilitates the ability to identify kinship. "These findings are in agreement with previous studies on the social differences between the sexes: women tend to be more communal and familial in their behavior, whereas men are more inclined to be competitive and striving to improve their social status", said Prof. Simone Shamay-Tsoory from the Dept. of Psychology at the University of Haifa who led the research.

1 Aug 2013

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.

31 Jul 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Placebo News and Research

Patients with IBS-D treated with eluxadoline achieve better clinical response

Omeros announces financial results for second quarter of 2013

Dopamine responses to alcohol ingestion may serve as marker of vulnerability to AUDs

Researchers discover new treatment for children with fragile bone disease

Probiotic supplements have no effect on the incidence of diarrhoea in elderly patients

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Added benefit of thyroid cancer drug vandetanib not proven

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

New technique accelerate tissue repair, reduce costs for chronic wound management

Pharmanest announces positive results from SHACT Phase II study

Experts say action needed urgently to ensure India's new policy does not backfire

Oxytocin hormone affects men and women differently, research finds

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News